Inflammatory bowel disease: Pandora's box, present and future

Annals of the New York Academy of Sciences

Volumn 1072, Issue , 2006, Pages 365-378

  Schölmerich, Jürgen ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Bacteria; Biologicals; Etiology; Inflammatory bowel disease; Pathophysiology; Probiotics

Indexed keywords

AZATHIOPRINE; BUDESONIDE; GLUCOCORTICOID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREBIOTIC AGENT; PREDNISONE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; STEROID;

CONFERENCE PAPER; CROHN DISEASE; DRUG EFFICACY; ENTERITIS; EPITHELIUM; HUMAN; IMMUNOSTIMULATION; MUCOSAL IMMUNITY; NONHUMAN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; STANDARD; TREATMENT INDICATION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

BACTERIA (MICROORGANISMS);

EID: 33749013297     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1326.026     Document Type: Conference Paper

References (48)

1. OGURA, Y. et al. 2001. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411: 603-606.
2. HUGOT, J.P. et al. 2001. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411: 599-603.
3. HAMPE, J. et al. 2001. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 357: 1925-1928.
4. WATANABE, T. et al. 2004. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. 5: 800-808.
5. WEHKAMP, J. et al. 2004. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 53: 1658-1664.
6. HOOPER, L.V et al. 2001. Molecular analysis of commensal host-microbial relationships in the intestine. Science 29: 881-884.
7. HOLLER, E. et al. 2004. Both, donor and recipient NOD 2/CARD15 mutations associate with transplant-related mortality and gastrointestinal GvHD following allogeneic stem cell transplantation. Blood 104: 889-894.
8. GENT, A.E. et al. 1994. Inflammatory bowel disease and domestic hygiene in infancy. Lancet 343: 766-767.
9. PELTEKOVA, V.D. et al. 2004. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat. Genet. 36: 471-475.
10. STOLL, M. et al. 2004. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat. Genet. 36: 476-480.
11. SCHWAB, M. et al. 2003. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 124: 26-33.
12. PASARE, C. & R. MEDZHITOV. 2003. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 299: 1033-1036.
13. OBERMEIER, F. et al. 2005. In vivo CpG DNA/toll like receptor 9 interection induces regulatory properties in CD4+CD62L+ T cells which prevent intestinal inflammation in the SCID transfer model of colitis. GUT 54: 1428-1436.
14. GASCHÉ, C. et al. 2000. A Simple Classification of Crohn's Disease. Inflamm. Bowel. Dis. 6: 8-15.
15. BEUTLER, B. 2001. Autoimmunity and apoptosis: the Crohn's connection. Immunity 15: 5-14.
16. SCHÖLMERICH, J. & G. HUBER. 2003. Biological therapies in IBD-anti TNFα and others. Dig. Dis. 21: 180-191.
17. KORNBLUTH, A.A. et al. 1993. Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis. J. Clin. Gastroenterol. 16: 215-218.
18. SILVERSTEIN, M.D. et al. 1999. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 117: 49-57.
19. FAUBION, W.A. Jr. et al. 2001. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121: 255-260.
20. WINTHER, K.V. et al. 2003. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen county. Gastroenterology 125: 1576-1582.
21. COSNES, J. et al. 2001. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 120: 1093-1099.
22. SCHWARTZ, D.A. et al. 2002. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology 122: 875-880.
23. REDDY, S.I. et al. 2005. Are patients with inflammatory bowel disease receiving optimal care? Am. J. Gastroenterol. 100: 1357-1361.
24. MARTEAU, P. et al. 2005. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54: 960-965.
25. CANDY, S. et al. 1995. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37: 674-678.
26. HANAUER, S.B. et al. 2002. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541-1549.
27. SANDS, B.E. et al. 2004. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II study. Clin. Gastroenterol. Hepatol. 2: 912-920.
28. RUTGEERTS, P. et al. 2005. A randomized placebo-controlled trial of infliximab therapy for active ulcerative colitis: Act I trial. Gastroenterology 128: A105.
29. SANDBORN, W.J. et al. 2005. Infliximab induction and maintenance therapy for ulcerative colitis: the Act 2 trial. Gastroenterology 128: A104.
30. JÄRNEROT, G. et al. 2005. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128: 1805-1811.
31. SCHREIBER, S. et al. 2003. CDP870, a humanized anti-TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease. Gastroenterology 125: 606.
32. SINHA, A. et al. 2003. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N. Engl. J. Med. 349: 350-357.
33. KORZENIK, J., A. PITTLER & B. DIECKGRAEFE. 2002. Immunostimulation in Crohn's disease: retreatment and maintenance therapy with GM-CSF. Gastroenterology 122: A432-A433.
34. SCHÖLMERICH, J. 2005. Biological therapies. In The Inflammatory Bowel Disease Yearbook. C. N. Bernstein, Ed., pp 111-139.
35. HOMMES, D. et al. 2005. Management of recent onset Crohn's disease: a controlled, randomized trial comparing step-up and top-down therapy. Gastroenterology 129: 371.
36. OBERMEIER, F. et al. 2003. Contrasting activity of cytosine-guanosin dinucleotide oligonucleotides in mice with experimental colitis. Clin. Exp. Immunol. 134: 217-224.
37. SCHULTZ, M., J. SCHÖLMERICH & H.C. RATH. 2003. Rationale for probiotic and antibiotic strategies in inflammatory bowel diseases. Dig. Dis. 21: 105-128.
38. KRUIS, W. et al. 2004. Maintaining remission of ulcerative colitis with the probiotic E. coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617-1623.
39. GIONCHETTI, P. et al. 2000. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis. A double-blind, placebo-controlled trial. Gastroenterology 119: 305-309.
40. GIONCHETTI, P. et al. 2003. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124: 1202-1209.
41. PRANTERA, C. et al. 2002. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomized controlled trial with Lactobacillus GG. Gut 51: 405-409.
42. MARTEAU, P. et al. 2006. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease-a randomized, double-blind, placebo-controlled GETAID trial. Gut 55: 842-847.
43. BIBILONI, R. et al. 2005. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol. 100: 1539-1546.
44. LINDSAY, J.O. et al. 2006. Clinical, microbiological and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut, 348-355.
45. STREMMEL, W. et al. 2005. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut 54: 966-971.
46. SUMMERS, R.W. et al. 2005. Trichuris suis therapy in Crohn's disease. Gut 54: 87-90.
47. SUMMERS, R.W. et al. 2005. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128: 825-832.
48. JESS, T. et al. 2006. Survival and cause-specific mortality in patients with inflammatory bowel disease: a long-term outcome study in Olmsted County, Minnesota, 1940-2004. Gut, doi: 10.1136/gut.2005.079350.